Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by xanseroon Feb 12, 2021 12:12pm

164 Views

Post# 32553048

New Medical Tech

Sponsored post

Have you heard about these medical technology markets and potentially seeing strong performance? Better to check this article

Mobile cardiac telemetry (MCT) is a cardiac monitoring method that uses a small portable device to monitors a patient’s cardiac activity. It records the patient’s heartbeat as they run errands, exercise, and sleep.

Moreover there's these a medical technology companies that claims to focus on delivering innovative and remote biometric monitoring solutions to the healthcare and consumer markets.

Check disclaimer on profile and landing page

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages